Despite the successes of biologic therapies in rheumatoid arthritis (RA), not all patients respond to available drugs, and systemic toxicity of some drugs often lead to therapy discontinuation. New developments in polymer–drug conjugates and nanoparticle technology can improve drug efficacy in patients with RA by targeting therapeutic agents to inflamed tissues and extending the half-life of drugs. In this Review, Ferrari and colleagues describe new techniques being explored to improve accumulation of therapeutic agents in the inflamed synovium—a new strategy to boost drug efficacy at disease sites without affecting healthy tissues.
- Mathieu Ferrari
- Shimobi C. Onuoha
- Costantino Pitzalis
